Healthcare: Top 3 Drug Approvals of 2015

Industry Focus

The Motley Fool

Interview, Money, Consumergoods, Business, Businessnews, Ceo, Technology, Investing, Stocks, Energy, Fool, Financial, Economy, Healthcare, News, Banking, Motley, Tech, Business News, Investments

4.6 • 854 Ratings

🗓️ 2 December 2015

⏱️ 21 minutes

🔗️ Recording | iTunes | RSS

🧾️ Download transcript

Summary

This episode we're highlighting what we think are the most significant, needle-moving drugs to hit the market this year.

Transcript

Click on a timestamp to play from that location

0:00.0	Top three drug approvals of 2015. This is Industry Focus.
0:07.0	Welcome to Industry Focus, everyone.
0:12.6	Health Care Edition.
0:13.6	I'm your host Christine Hargis.
0:15.0	I've got Todd Campbell on Skype.
0:17.0	Hi Todd.
0:18.2	Hi Todd. Hi, how are you?
0:19.2	How is your turkey day?
0:20.6	Great. I'm still full.
0:21.8	Still working through left-over. That is quite literally what I will do as soon as we finish taping the show is go eat some more left-erbers. How is yours?
0:28.0	Fantastic.
0:30.0	Do you have a good one?
0:31.0	Yeah, it was good. I think I'm done though.
0:34.0	I could go another month without some turkey.
0:37.0	Oh, no why.
0:38.0	It's my absolute favors Thanksgiving food.
0:39.5	I'll eat it until it runs out. So as I kick the show off with we are talking about the top three
0:45.7	drug approvals of 2015 but it's kind of hard to make the statement of top three I
0:50.9	mean that depends on how you measure it right so are we talking
0:53.5	significance in the indication or biggest needle mover for the company I mean you could
0:59.4	say highest peak sales biggest patient population there are a million
1:02.1	ways that you could probably answer,
	...

Please login to see the full transcript.

Previous episode | Next episode

Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.